ZOETIS INC.

ZTS trades at a compelling 17.8 P/E despite sitting near 52-week highs, suggesting the market hasn't fully priced in growth potential for this $49.6B animal health leader. The RSI of 40.5 signals oversold conditions without capitulation, while minimal short interest at 3.63% indicates no squeeze risk—just steady institutional positioning. This valuation discount relative to pharma peers combined with intermediate technical weakness presents an interesting asymmetry: either the stock has further to run as fundamentals justify the multiple, or the market is correctly pricing caution. The setup lacks the desperation of a washout but also the exuberance of a breakout, making this a study in patient conviction rather than tactical timing.